PREVALENCE OF PSILOCYBE CUBENSIS USE IN THAILAND
Keywords:
Psilocybin mushrooms, Prevalence, ThailandAbstract
An up-to-date understanding of psychoactive plant use is essential for developing effective strategies to mitigate its widespread impact. This descriptive study aimed to estimate the population size of Thai individuals using Psilocybe cubensis (commonly known as "magic mush-rooms") in 2024. A cross-sectional household survey was conducted using a five-stage stratified sampling technique. Thailand was divided into 10 regions, and systematic random sampling was performed at the provincial, sub-district, and community levels. Households were selected systematically based on the most recent updated community maps. Within each selected household, members were stratified by gender and randomly sampled using random number tables. A total of 34,410 individuals participated in the study. Data were collected between March and October 2024 through structured face-to-face interviews. Data analysis employed both descriptive and inferential statistics, including frequency distribution, percentage, odds ratio (OR), 95% confidence intervals (CI), point estimation, chi-square test, Fisher’s exact test, and multiple logistic regression.
The findings indicated that 12,912 Thais aged 12–65 years had used Psilocybe cubensis, corresponding to a prevalence rate of 26.32 per 100,000 populations. The prevalence was higher among males (40.74 per 100,000) compared to females (12.35 per 100,000). Among youth, the prevalence was 6.45 per 100,000, while in adults it was 32.16 per 100,000. A statistically significant association (p < 0.05) was observed between psilocybin mushroom use and concurrent use of other illicit substances. Individuals who used other drugs were 42.8 times more likely to engage in high-risk behaviors associated with psilocybin use (AOR = 42.817, 95% CI = 16.508–111.055, p < 0.001).
Downloads
References
United Nations Office on Drugs and Crime (UNODC). World Drug Report 2024. Vienna: United Nations publication; 2024.
Merlin MD. Archaeological evidence for the tradition of psychoactive plant use in the old world. Economic Botany 2003; 57(3): 295-323.
Sullivan RJ, Hagen EH. Psychotropic substance‐seeking: evolutionary pathology or adaptation?. Addiction 2002; 97(4): 389-400.
Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology 2017; 42(11): 2105-2113.
Kanato M, Leyatikul P, Wonguppa R. The Synthesis of Illicit Drugs Situation in Thailand 2024. Nakhonratchasima: Addiction Science Center, Vongchavalitkul University; 2024. [in Thai].
Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 2006; 187(3): 268-283.
Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl) 2018; 235(2):399-408. doi: 10.1007/s00213-017-4771-x.
Nichols DE. Psychedelics. Pharmacological Reviews 2016. 68(2); 264-355.
Murray B, Harrison J, Kelly K. Phencyclidine (PCP) intoxication: Clinical effects and management. Substance Abuse 2013; 34(1): 39-46.
Halpern JH, Pope HG. Hallucinogen persisting perception disorder: What do we know? Drug and Alcohol Dependence 2003; 69(2): 109-119.
Parrott AC. MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational 'Ecstasy' users. Neuroscience & Biobehavioral Reviews 2013; 37(8): 1466-1484.
Couch R, Brown S, Smirk C. MDMA: A case of myocardial ischemia. International Journal of Cardiology 2019; 278: 134-136.
Domínguez-Clavé E, Soler J, Elices M, et al. Ayahuasca: Pharmacology, neuroscience and therapeutic potential. Brain Research Bulletin 2016; 126: 89-101.
Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nature Reviews Neuroscience 2010; 11(9): 642-651.
Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen, M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry 2016; 3(7): 619-627.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles in this journal are copyrighted by the x may be read and used for academic purposes, such as teaching, research, or citation, with proper credit given to the author and the journal.use or modification of the articles is prohibited without permission.
statements expressed in the articles are solely the opinions of the authors.
authors are fully responsible for the content and accuracy of their articles.
other reuse or republication requires permission from the journal."